Quick Answer
ZyVersa Therapeutics, Inc. reported Stockholders Equity of -$12.39 million for fiscal year 2025.
ZyVersa Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$12.39M | -245.4% |
| 2024 | $8.52M | -23.1% |
| 2023 | $11.07M | -88.9% |
| 2022 | $99.66M | -0.0% |
| 2022 | $99.68M | +4513.7% |
| 2021 | -$2.26M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.73M | -266.9% | -292.2% |
| June 30, 2025 | $6.10M | -29.2% | -25.0% |
| March 31, 2025 | $8.13M | -27.6% | -4.5% |
| December 31, 2024 | $8.52M | -23.1% | +21.2% |
| September 30, 2024 | $7.03M | -64.3% | -18.5% |
| June 30, 2024 | $8.62M | -57.0% | -23.2% |
| March 31, 2024 | $11.22M | -88.4% | +1.3% |
| December 31, 2023 | $11.07M | -88.9% | -43.8% |
- ZyVersa Therapeutics, Inc. showed a decrease of -245.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, ZyVersa Therapeutics, Inc.’s stockholders equity has declined by 448.5% (from -$2.26 million to -$12.39 million).
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: